Saccaro notified the company on July 21 that he plans to resign for a role “outside of the medical technology industry.” That role remains yet to be disclosed. He set Aug. 14, 2026, as his final day with the Chicago-based medtech giant.
Today, GE HealthCare said it named George Newcomb, its controller and chief accounting officer, as interim CFO, effective Aug. 14. The company also said it began the search process for a permanent successor.
Saccaro left Baxter, where he served as CFO as well, for the same post at GE HealthCare in 2023. Before his eight-year stint as Baxter CFO, Saccaro also served as SVP and CFO at Hillrom. He previously held the role of VP and treasurer at Baxter, having initially joined in 2002 as manager of strategy for its BioScience business.
Newcomb became controller of the healthcare business of GE in February 2016. He became controller and chief accounting officer of GE HealthCare in January 2023 in connection with the company’s spin-off from GE. Newcomb spent 20 years in a variety of finance leadership roles at GE Capital between 1996 and 2016 as well.
Commentary from GE HealthCare officials
Saccaro said:
“It has been a privilege to serve as GE HealthCare’s CFO and lead its outstanding finance organization. I want to thank Peter, the Board, and my colleagues for their partnership over the past three years, and I wish the company continued success.”
GE HealthCare president and CEO Peter Arduini said:
“On behalf of the board of directors and executive team, I would like to thank Jay for his contributions over the past three years. He has played a key role in driving financial discipline and strategic investments aligned to our capital allocation strategy. We wish him success in his next endeavor.”
Preliminary Q2 results
GE HealthCare also reported preliminary results for its second quarter, which ended on June 30, 2026.
The company expects to report year-over-year revenue growth of 5.7%. It expects its diluted and adjusted earnings per share (EPS) to land ahead of its previous forecast.
Arduini said:
“We are pleased with the momentum in our business, reflecting strong orders, healthy end market demand, traction with new products, and continued commercial execution.”
